Bulking agent showing durable SUI control at 1 year

Women given investigational agent show dry, improved outcomes more often than controls

Related Content:

Drug Therapy

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

FDA approves androgen inhibitor for metastatic PCa